Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study

Jaime Lora-Tamayo,Guillermo Maestro,Antonio Lalueza,Manuel Rubio-Rivas, Gracia Villarreal Paul,Francisco Arnalich Fernández,José Luis Beato Pérez,Juan Antonio Vargas Núñez,Mónica Llorente Barrio,Carlos Lumbreras Bermejo

Journal of Infection（2021）

引用 8|浏览1

暂无评分

摘要

•This is the largest study assessing the efficacy of LPV/r against SARS-CoV-2.•The overall use of LPV/r was not associated with lower mortality in CoVID19 patients.•The early use of LPV/r (median 5 days) showed no benefit either.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要